Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ensovibep · 1 trial · 1 indication
Changes from baseline to each time point of measurement in SARS-CoV-2 viral load in nasopharyngeal swabs
Changes from baseline to each time point of measurement in SARS-CoV-2 viral cultures cultivated from nasopharyngeal swabs
Duration in days to SARS-CoV-2 PCR negativity
The maximum observed concentration (Cmax) is estimated based on the serum concentrations.
| Arm | Type | Description |
|---|---|---|
| ensovibep dose 1 | EXPERIMENTAL | - |
| ensovibep dose 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ensovibep | DRUG | The study will start with a low-dose cohort and after a safety review escalate to the higher dose cohort. One administration at day 1 by infusion. |
Inclusion Criteria: * Men or non-pregnant women, between 18 and 70 years on the day of inclusion. * Presence of one or more mild or moderate COVID-19 symptoms: Fever, cough, sore throat, malaise, fatigue, headache, muscle pain, gastrointestinal symptoms, or shortness of breath with exertion. * Posi...
Ensovibep is an investigational small molecule being studied for the treatment of Covid-19. It is being developed by Molecular Partners AG (ticker: MOLN) and has completed a Phase 2 clinical trial in patients with Covid-19.
Ensovibep is being developed by Molecular Partners AG, a biopharmaceutical company listed on the SIX Swiss Exchange under the ticker MOLN. The company is conducting clinical research on ensovibep as a potential treatment for Covid-19.
Ensovibep is in Phase 2 clinical development. A Phase 2 trial has been completed, and the drug remains investigational, meaning it has not been approved by regulatory authorities. Further clinical development may be required before any potential approval.
Ensovibep has been studied in one completed Phase 2 clinical trial, identified as NCT04834856, titled 'Viral Clearance, PK and Tolerability of Ensovibep in COVID-19 Patients'. This trial enrolled 12 participants in the Netherlands and was a controlled study.
Ensovibep is not known to be the same as any other drug. It is a distinct investigational small molecule being developed by Molecular Partners AG for Covid-19. No alternative names have been reported for ensovibep.